Marstacimab-hncq Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Marstacimab-hncq Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
11
Registered trials
10
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Marstacimab-hncq can convert its Monoclonal antibody profile and TFPI biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Marstacimab-hncq (query alias: marstacimab) |
|---|---|
| Modality / target | Monoclonal antibody; TFPI; TFPI inhibitors |
| Highest global status | Approved |
| Originator | Pfizer Inc. |
| Active developers | Pfizer Inc., Pfizer Europe MA EEIG, Pfizer Investment Co. Ltd. |
The MCP disease footprint includes Hemophilia A, Hemophilia B, Midface hypoplasia, mild to severe. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05611801 | Phase 3 | Recruiting | 100 | Annualized bleeding rate (ABR) of treated bleeding events |
| NCT06703606 | Phase 1 | Recruiting | 15 | Incidence of marstacimab-related adverse events (AEs) |
| NCT06992076 | Not Applicable | Recruiting | 100 | patient preferences for subcutaneous |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints: Results from BASIS and OLE studies
Phase 3; n=116; evaluation: Positive. Reported fields: Annualized bleeding rate(treated TJ bleeds) = 2.29 Event ( 5.52)
Outcomes of marstacimab treatment in adolescent participants with Hemophilia A or B without inhibitors compared with prior routine prophylaxis: Results from the phase 3 BASIS trial
Phase 3; n=17; evaluation: Positive. Reported fields: AE = 11.0 Event ; AE = 36.0 Event
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: ABR(12-month) = 19.78 % Met; ABR(12-month) = 1.39 % Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Marstacimab-hncq addresses Hemophilia A, Hemophilia B, Midface hypoplasia, mild to severe. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TFPI records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-17 | Nanolek and Alphamab have entered into an agreement to launch a drug for the prevention of bleeding in hemophilia patients across Eurasian countries. | Phase 3 | Financial terms not disclosed |
| 2023-09-20 | 苏州康宁杰瑞与远大生命科学集团就TFPI单克隆抗体KN057达成合作 | Phase 2 | US$500.0M stated total |
| 2010-11-19 | Baxter Announces Acquisition of All Hemophilia-Related Assets of Archemix and an Exclusive License of Its Anti-TFPI Aptamer Technology | Phase 1 | US$30.0M upfront; US$285.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Stable aqueous Anti-TFPI antibody formulation”. The milestone feed surfaced a patent-application signal described as “Dosage regimen for TFPI antagonists”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
